ET
RARE icon

Entropy Technologies’s Ultragenyx Pharmaceutical RARE Stock Holding History

Entropy Technologies’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48M Sell
44,345
-65,382
-60% -$1.62M 0.06% 406
2026
Q1 		$2.3M Buy
109,727
+49,086
+81% +$1.11M 0.11% 255
2025
Q4 		$1.39M Buy
60,641
+40,577
+202% +$1.33M 0.08% 315
2025
Q3 		$604K Buy
20,064
+8,728
+77% +$262K 0.05% 469
2025
Q2 		$412K Buy
11,336
+3,787
+50% +$137K 0.03% 535
2025
Q1 		$273K Buy
+7,549
New +$314K 0.03% 559

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Entropy Technologies's RARE Position: Q2 2026 in Review

Entropy Technologies reduced its Ultragenyx Pharmaceutical (RARE) stake by 60% in Q2 2026, selling an estimated $1.62M and leaving 44,345 shares worth $1.48M. The position accounts for 0.06% of the portfolio, ranked #406.

Entropy Technologies first reported a position in RARE in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.3M in Q1 2026. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Entropy Technologies held 44,345 shares of Ultragenyx Pharmaceutical worth $1.48M as of Q2 2026.
  • Entropy Technologies sold 65,382 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $1.62M.
  • Ultragenyx Pharmaceutical made up 0.06% of Entropy Technologies's portfolio in Q2 2026, its #406 holding.
  • Entropy Technologies first reported a position in Ultragenyx Pharmaceutical in Q1 2025 and has held it in 6 quarters since.
  • Entropy Technologies's Ultragenyx Pharmaceutical position peaked at $2.3M in Q1 2026.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Entropy Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.